|
Dr. Szakacs joined Chelsea Therapeutics from Nektar Therapeutics where he was responsible for running preclinical programs, including toxicology, safety pharmacology and proof-of-concept efficacy studies. Previously, Dr. Szakacs oversaw clinical development programs for Endpoint Research (a Canadian clinical research organization) as a Project Director with an emphasis on oncology molecules. Previously he had worked for 5 years with Hoffmann La-Roche in numerous capacities within their Development organization. Dr. Szakacs also taught, and conducted both animal and human pharmacology research at the University of Saskatchewan, where he received his Ph.D. in Pharmacology. | 